212 related articles for article (PubMed ID: 15877230)
1. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
2. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
4. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
5. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
6. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
7. Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Phillips RM; Burger AM; Loadman PM; Jarrett CM; Swaine DJ; Fiebig HH
Cancer Res; 2000 Nov; 60(22):6384-90. PubMed ID: 11103802
[TBL] [Abstract][Full Text] [Related]
8. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
9. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
10. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
14. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
15. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
Dehn DL; Inayat-Hussain SH; Ross D
J Pharmacol Exp Ther; 2005 May; 313(2):771-9. PubMed ID: 15665137
[TBL] [Abstract][Full Text] [Related]
16. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
Danson S; Ranson M; Denneny O; Cummings J; Ward TH
Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
[TBL] [Abstract][Full Text] [Related]
17. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
Wang X; Wang G; Dong D; Fu S; Yang B
Exp Toxicol Pathol; 2008 Sep; 60(6):481-8. PubMed ID: 18606528
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis.
Lau CB; Ho CY; Kim CF; Leung KN; Fung KP; Tse TF; Chan HH; Chow MS
Life Sci; 2004 Jul; 75(7):797-808. PubMed ID: 15183073
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
Park MT; Song MJ; Oh ET; Lee H; Choi BH; Jeong SY; Choi EK; Park HJ
Br J Pharmacol; 2011 Jun; 163(3):567-85. PubMed ID: 21250978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
